This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
120
QLC7401 is a small interfering RNA (siRNA) targeting PCSK9. Administered as subcutaneous injection at a specified dose level.
Placebo matching QLC7401 in appearance and administration.
Percent Change in LDL-C from Baseline
Time frame: From baseline to Day 360
Incidence of Treatment-Emergent Adverse Events
Time frame: From baseline to Day 360
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.